Zinbryta (ABT-803) is a CD25 antagonist antibody therapy being investigated for relapsing forms of multiple sclerosis.

Type of Molecule

Biologic

Target

CD25

Region

US, EU

Potential Indication Product Type Phase (1, 2, 3, Submitted, Approved)
Multiple Sclerosis (MS) New Indication Phase Approved Approved